title: Novel immune assay for quantification of plasma protective capacity against oxidized phospholipids.
abstract: OBJECTIVE
  Oxidized phospholipids (OxPL) are the major pathogenic component of oxidized low-density lipoproteins (OxLDL). Endogenous anti-OxPL activity, defined as the ability to neutralize adverse effects of oxidized lipids, may have biomarker potential.
  
  
  RESULTS
  Using two anti-OxPL monoclonal antibodies (commercial mAB-E06 and custom mAB-509) we developed a novel ELISA that measures the global capacity of plasma to inactivate OxPL. Preincubation of OxLDL with plasma inhibits its binding of anti-OxPL mABs. This phenomenon ('masking') reflects anti-OxPL plasma activity. A pilot clinical application of the assay revealed reduced anti-OxPL activity in hypertension, coronary artery disease, acute coronary syndrome and diabetes.
  
  
  CONCLUSIONS
  Inadequate anti-OxPL protection may contribute to cardiovascular disease and have biomarker potential in conditions associated with abnormal lipid peroxidation.
authors.affiliation: Institute of Pharmaceutical Sciences, University of Graz, Austria.
authors.forename: Valery
authors.initials: V
authors.lastname: Bochkov
authors.affiliation: Division of Geriatrics, Department of General Internal Medicine, Inselspital, Bern University Hospital & University of Bern, Bern, Switzerland.
authors.forename: Andreas W
authors.initials: AW
authors.lastname: Schoenenberger
authors.affiliation: Institute of Pharmaceutical Sciences, University of Graz, Austria.
authors.forename: Olga
authors.initials: O
authors.lastname: Oskolkova
authors.affiliation: Department of Vascular Biology & Thombosis Research, Medical University of Vienna, Vienna, Austria.
authors.forename: Ursula
authors.initials: U
authors.lastname: Toth
authors.affiliation: Institute of Immunology, Medical University of Vienna, Vienna, Austria.
authors.forename: Johannes
authors.initials: J
authors.lastname: Stöckl
authors.affiliation: Institute of Immunology, Medical University of Vienna, Vienna, Austria.
authors.forename: Otto
authors.initials: O
authors.lastname: Majdic
authors.affiliation: Department of Vascular Biology & Thombosis Research, Medical University of Vienna, Vienna, Austria.|Department of Pharmacy, Faculty of Medicine, University of Prishtina, Kosovo.
authors.forename: Armond
authors.initials: A
authors.lastname: Daci
authors.affiliation: Signaling Laboratory, Department of Biomedicine, Basel University Hospital, Basel, Switzerland.
authors.forename: Thérèse J
authors.initials: TJ
authors.lastname: Resink
authors.affiliation: Signaling Laboratory, Department of Biomedicine, Basel University Hospital, Basel, Switzerland.
authors.forename: Paul
authors.initials: P
authors.lastname: Erne
authors.affiliation: Signaling Laboratory, Department of Biomedicine, Basel University Hospital, Basel, Switzerland.
authors.forename: Maria
authors.initials: M
authors.lastname: Philippova
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000473:pathology; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology; D001774:Blood Chemical Analysis / Q000379:methods*; D003324:Coronary Artery Disease / Q000097:blood / Q000473:pathology; D003920:Diabetes Mellitus / Q000097:blood / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000473:pathology; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D010743:Phospholipids / Q000097:blood* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D008077:Lipoproteins, LDL; D010743:Phospholipids; C099252:oxidized low density lipoprotein
keywords: ELISA; anti-oxidized phospholipid antibodies; anti-oxidized phospholipid defense; biomarker potential; cardiovascular disease; oxidized phospholipids